RxDoctor Payments Data

Josette Grice, MD

Family Medicine · Bradenton, FLNPI 1922070630

Payments from drug & device makers

$418in general payments, 2019–2025

Across 15 payments — averaging $27.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Centinel Spine, LLC$133
  • AbbVie$106
  • Exact Sciences$55
  • Nevro Corp.$30
  • Millicent US Inc$27
  • Novo Nordisk$19
  • plus $48 from 3 others

What the payments were for

  • Food & beverage$37489%
  • Education$276%
  • Gifts$184%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Centinel Spine, LLC1$133
AbbVie5$106
Exact Sciences2$55
Nevro Corp.1$30
Millicent US Inc2$27
Novo Nordisk1$19
Ascend Therapeutics US, LLC1$18
Phathom Pharmaceuticals, Inc.1$16
Boston Scientific1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$418 in reported general payments places this provider in the 45th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$268,054
Medicare patients
787
Services billed
9,941

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide86$87,521
MounjaroTirzepatide56$66,996
EliquisApixaban56$57,661
JanuviaSitagliptin Phosphate35$38,187
TrulicityDulaglutide35$35,952
FarxigaDapagliflozin Propanediol32$34,125
LinzessLinaclotide26$19,094
TrintellixVortioxetine Hydrobromide13$14,709
JanumetSitagliptin Phos/Metformin Hcl12$11,232
SymbicortBudesonide/Formoterol Fumarate36$9,814
Advair HfaFluticasone Propion/Salmeterol15$8,010
NexletolBempedoic Acid19$7,401
Breo ElliptaFluticasone/Vilanterol14$5,525
Estradiol84$5,225
TirosintLevothyroxine Sodium25$4,429

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$19$87,52186 claims
AbbVieLinzess, Synthroid$106$23,26790 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →